The immunomodulatory-drug, lenalidomide, sustains and enhances interferon-α production by human plasmacytoid dendritic cells

References

• Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371(10):906–917. doi:10.1056/NEJMoa140255125184863
   PubMed Web of Science ®Google Scholar
• Paiva B, Mateos MV, Sanchez-Abarca LI, et al. Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis. Blood. 2016;127(9):1151–1162. doi:10.1182/blood-2015-10-66232026668134
   PubMed Web of Science ®Google Scholar
• Gandhi AK, Kang J, Capone L, et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets. 2010;10(2):155–167.20088798
   PubMed Web of Science ®Google Scholar
• Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98(1):210–216. doi:10.1182/blood.v98.1.21011418482
   PubMed Web of Science ®Google Scholar
• Wu L, Adams M, Carter T, et al. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res. 2008;14(14):4650–4657. doi:10.1158/1078-0432.CCR-07-440518628480
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002;99(12):4525–4530. doi:10.1182/blood.v99.12.452512036884
   PubMed Web of Science ®Google Scholar
• Schafer PH, Gandhi AK, Loveland MA, et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther. 2003;305(3):1222–1232. doi:10.1124/jpet.102.04849612649301
   PubMed Web of Science ®Google Scholar
• Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol. 2008;140(1):36–45. doi:10.1111/j.1365-2141.2007.06841.x17995965
   PubMed Web of Science ®Google Scholar
• Galustian C, Meyer B, Labarthe MC, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother. 2009;58(7):1033–1045. doi:10.1007/s00262-008-0620-419009291
   PubMed Web of Science ®Google Scholar
• Luptakova K, Rosenblatt J, Glotzbecker B, et al. Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother. 2013;62(1):39–49. doi:10.1007/s00262-012-1308-322733396
   PubMed Web of Science ®Google Scholar
• Benson DM, Bakan CE, Mishra A, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood. 2010;116(13):2286–2294. doi:10.1182/blood-2010-02-27187420460501
   PubMed Web of Science ®Google Scholar
• Görgün G, Samur MK, Cowens KB, et al. Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma. Clin Cancer Res. 2015;21(20):4607–4618. doi:10.1158/1078-0432.CCR-15-020025979485
   PubMed Web of Science ®Google Scholar
• Siegal FP, Kadowaki N, Shodell M, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science. 1999;284(5421):1835–1837.10364556
   PubMed Web of Science ®Google Scholar
• Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol. 2005;23:275–306. doi:10.1146/annurev.immunol.23.021704.11563315771572
   PubMed Web of Science ®Google Scholar
• Ito T, Kanzler H, Duramad O, Cao W, Liu Y-J. Specialization, kinetics, and repertoire of type 1 interferon responses by human plasmacytoid predendritic cells. Blood. 2006;107(6):2423–2431. doi:10.1182/blood-2005-07-270916293610
   PubMed Web of Science ®Google Scholar
• Trinchieri G, Santoli D. Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis. J Exp Med. 1978;147(5):1314–1333. doi:10.1084/jem.147.5.1314650156
   PubMed Web of Science ®Google Scholar
• Le Bon A, Schiavoni G, D’Agostino G, Gresser I, Belardelli F, Tough DF. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity. 2001;14(4):461–470.11336691
   PubMed Web of Science ®Google Scholar
• Le Bon A, Etchart N, Rossmann C, et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol. 2003;4(10):1009–1015. doi:10.1038/ni97814502286
   PubMed Web of Science ®Google Scholar
• Ito T, Wang YH, Liu YJ. Plasmacytoid dendritic cell precursors/type I interferon-producing cells sense viral infection by Toll-like receptor (TLR) 7 and TLR9. Springer Semin Immunopathol. 2005;26(3):221–229. doi:10.1007/s00281-004-0180-415592841
   PubMed Web of Science ®Google Scholar
• Henry JY, Labarthe MC, Meyer B, Dasgupta P, Dalgleish AG, Galustian C. Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs® immunomodulatory compounds lenalidomide and pomalidomide. Immunology. 2013;139(3):377–385. doi:10.1111/imm.1208723374145
   PubMed Web of Science ®Google Scholar
• Torii Y, Ito T, Amakawa R, et al. Imidazoquinoline acts as immune adjuvant for functional alteration of thymic stromal lymphopoietin-mediated allergic T cell response. J Immunol. 2008;181(8):5340–5349. doi:10.4049/jimmunol.181.8.534018832690
   PubMed Web of Science ®Google Scholar
• Ito T, Inaba M, Inaba K, et al. A CD1a+/CD11c+ subset of human blood dendritic cells is a direct precursor of Langerhans cells. J Immunol. 1999;163(3):1409–1419.10415041
   PubMed Web of Science ®Google Scholar
• Iida S, Chou T, Okamoto S, et al. Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma. Int J Hematol. 2010;92(1):118–126. doi:10.1007/s12185-010-0624-720559759
   PubMed Web of Science ®Google Scholar
• Moreau P, Karamanesht II, Domnikova N, et al. Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. Clin Pharmacokinet. 2012;51(12):823–829. doi:10.1007/s40262-012-0010-023018466
   PubMed Web of Science ®Google Scholar
• Hirai M, Kadowaki N, Kitawaki T, et al. Bortezomib suppresses function and survival of plasmacytoid dendritic cells by targeting intracellular trafficking of Toll-like receptors and endoplasmic reticulum homeostasis. Blood. 2011;117(2):500–509. doi:10.1182/blood-2010-05-28473720956804
   PubMed Web of Science ®Google Scholar
• Chanan-Khan AA, Swaika A, Paulus A, et al. Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. Blood Cancer J. 2013;3:e143. doi:10.1038/bcj.2013.3824013664
   PubMed Web of Science ®Google Scholar
• POMALYST^® [PRESCRIBING INFORMATION]: Celgene Corporation. 2018.
   Google Scholar
• Brown RD, Pope B, Murray A, et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood. 2001;98(10):2992–2998. doi:10.1182/blood.v98.10.299211698282
   PubMed Web of Science ®Google Scholar
• Ratta M, Fagnoni F, Curti A, et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood. 2002;100(1):230–237. doi:10.1182/blood.v100.1.23012070032
   PubMed Web of Science ®Google Scholar
• Giannopoulos K, Kaminska W, Hus I, Dmoszynska A. The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma. Br J Cancer. 2012;106(3):546–552. doi:10.1038/bjc.2011.57522223085
   PubMed Web of Science ®Google Scholar
• Muthu Raja KR, Rihova L, Zahradova L, et al. Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma. PLoS One. 2012;7(10):e47077. doi:10.1371/journal.pone.004707723071717
   PubMed Web of Science ®Google Scholar
• Müller U, Steinhoff U, Reis LF, et al. Functional role of type I and type II interferons in antiviral defense. Science. 1994;264(5167):1918–1921.8009221
   PubMed Web of Science ®Google Scholar
• Lee CK, Rao DT, Gertner R, Gimeno R, Frey AB, Levy DE. Distinct requirements for IFNs and STAT1 in NK cell function. J Immunol. 2000;165(7):3571–3577. doi:10.4049/jimmunol.165.7.357111034357
   PubMed Web of Science ®Google Scholar
• Bogdan C, Mattner J, Schleicher U. The role of type I interferons in non-viral infections. Immunol Rev. 2004;202:33–48. doi:10.1111/j.0105-2896.2004.00207.x15546384
   PubMed Web of Science ®Google Scholar
• Trinchieri G, Santoli D, Granato D, Perussia B. Antagonistic effects of interferons on the cytotoxicity mediated by natural killer cells. Fed Proc. 1981;40(12):2705–2710.6169557
   PubMedGoogle Scholar
• Golding A, Rosen A, Petri M, Akhter E, Andrade F. Interferon-alpha regulates the dynamic balance between human activated regulatory and effector T cells: implications for antiviral and autoimmune responses. Immunology. 2010;131(1):107–117. doi:10.1111/j.1365-2567.2010.03280.x20465564
   PubMed Web of Science ®Google Scholar
• Ito T, Amakawa R, Inaba M, Ikehara S, Inaba K, Fukuhara S. Differential regulation of human blood dendritic cell subsets by IFNs. J Immunol. 2001;166(5):2961–2969. doi:10.4049/jimmunol.166.5.296111207245
   PubMed Web of Science ®Google Scholar
• Gautier G, Humbert M, Deauvieau F, et al. A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J Exp Med. 2005;201(9):1435–1446. doi:10.1084/jem.2004196415851485
   PubMed Web of Science ®Google Scholar
• Fink K, Lang KS, Manjarrez-Orduno N, et al. Early type I interferon-mediated signals on B cells specifically enhance antiviral humoral responses. Eur J Immunol. 2006;36(8):2094–2105. doi:10.1002/eji.20063599316810635
   PubMed Web of Science ®Google Scholar
• Le Bon A, Thompson C, Kamphuis E, et al. Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J Immunol. 2006;176(4):2074–2078. doi:10.4049/jimmunol.176.4.207416455962
   PubMed Web of Science ®Google Scholar
• Hanabuchi S, Watanabe N, Wang YH, et al. Human plasmacytoid predendritic cells activate NK cells through glucocorticoid-induced tumor necrosis factor receptor-ligand (GITRL). Blood. 2006;107(9):3617–3623. doi:10.1182/blood-2005-08-341916397134
   PubMed Web of Science ®Google Scholar
• Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science. 2001;294(5546):1540–1543. doi:10.1126/science.106489011711679
   PubMed Web of Science ®Google Scholar
• Fonteneau JF, Larsson M, Beignon AS, et al. Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells. J Virol. 2004;78(10):5223–5232. doi:10.1128/JVI.78.10.5223-5232.200415113904
   PubMed Web of Science ®Google Scholar
• Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity. 2003;19(2):225–234.12932356
   PubMed Web of Science ®Google Scholar
• Rothenfusser S, Hornung V, Ayyoub M, et al. CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro. Blood. 2004;103(6):2162–2169. doi:10.1182/blood-2003-04-109114630815
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906–917. doi:10.1056/NEJMoa080147918753647
   PubMed Web of Science ®Google Scholar
• VELCADE^® [product information]: Janssen. 2016.
   Google Scholar
• REVLIMID^® [Package Insert]. Summit, NJ: Celgene Corporation; 2017.
   Google Scholar
• Brimnes MK, Svane IM, Johnsen HE. Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma. Clin Exp Immunol. 2006;144(1):76–84. doi:10.1111/j.1365-2249.2006.03037.x16542368
   PubMed Web of Science ®Google Scholar
• Chauhan D, Singh AV, Brahmandam M, et al. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell. 2009;16(4):309–323. doi:10.1016/j.ccr.2009.08.01919800576
   PubMed Web of Science ®Google Scholar
• Uehira K, Amakawa R, Ito T, et al. Dendritic cells are decreased in blood and accumulated in granuloma in tuberculosis. Clin Immunol. 2002;105(3):296–303.12498811
   PubMed Web of Science ®Google Scholar
• Ozaki Y, Amakawa R, Ito T, et al. Alteration of peripheral blood dendritic cells in patients with primary Sjögren’s syndrome. Arthritis Rheum. 2001;44(2):419–431. doi:10.1002/1529-0131(200102)44:2<419::AID-ANR61>3.0.CO;2-U11229474
   PubMed Web of Science ®Google Scholar
• Ota M, Amakawa R, Uehira K, et al. Involvement of dendritic cells in sarcoidosis. Thorax. 2004;59(5):408–413. doi:10.1136/thx.2003.00604915115868
   PubMed Web of Science ®Google Scholar
• Takebayashi M, Amakawa R, Tajima K, et al. Blood dendritic cells are decreased in acute graft-versus-host disease. Bone Marrow Transplant. 2004;33(10):989–996. doi:10.1038/sj.bmt.170440615064686
   PubMed Web of Science ®Google Scholar
• Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782–1791. doi:10.1056/NEJMoa111413822571202
   PubMed Web of Science ®Google Scholar
• McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1770–1781. doi:10.1056/NEJMoa111408322571201
   PubMed Web of Science ®Google Scholar